Knowledge Ecology International
Knowledge Ecology International is a Washington, DC-based non-profit research and advocacy organization that conducts policy analysis and direct advocacy at the intersection of intellectual property, trade, and public health, engaging with WHO, WIPO, WTO, and US government agencies on access to medicines and related issues.
- Company typePrivate
- Founded2006
- HeadquartersWashington, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Knowledge Ecology International does
Knowledge Ecology International (KEI) is a Washington, DC-based non-profit research and advocacy organization operating at the intersection of intellectual property, trade policy, and public health. Headquartered at 110 Maryland Avenue NE, Washington, DC 20002, with an operational presence in Geneva, Switzerland, KEI engages in policy research, legal analysis, and direct advocacy before multilateral bodies including the World Health Organization (WHO), World Intellectual Property Organization (WIPO), and World Trade Organization (WTO), as well as US government agencies such as NIH, FDA, USTR, and HHS.
KEI's core outputs are research publications, briefing notes, formal statements delivered at international proceedings, and publicly accessible databases including DrugDatabase.Info and the KEI Collection on the Internet Archive, which consolidate FOIA documents, patent licenses, government contracts, and historical timelines on IP and access-to-medicine debates. The organization does not develop commercial software or technology products; its underlying "platform" is its institutional knowledge, document repositories, and direct forum access enabled by formal accreditation as a non-state actor at WHO.
KEI operates as a non-profit funded through donations and grants from individuals and organizations supportive of its mission to promote access to knowledge and affordable medicines. Its go-to-market is event-driven advocacy: participating in WHO, WIPO, and WTO negotiations, hosting side events at major conferences, delivering statements on agenda items such as the Pandemic Agreement PABS Annex and WIPO Broadcast Treaty, and submitting comments on US government licensing decisions (e.g., NIH exclusive licenses to entities like OncoVanta). It serves institutional stakeholders (WHO member states, US agencies), coalition partners (Health Action International, Oxfam, World Blind Union, World Council of Churches, UAEM, Medicines Law & Policy, Innovarte), and the broader public health advocacy community.
Knowledge Ecology International firmographics
Firmographics- Name
- Knowledge Ecology International
- Legal name
- Knowledge Ecology International
- Website
- https://keionline.org
- Company type
- Private
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Knowledge Ecology International is a Washington, DC-based non-profit research and advocacy organization that conducts policy analysis and direct advocacy at the intersection of intellectual property, trade, and public health, engaging with WHO, WIPO, WTO, and US government agencies on access to medicines and related issues.
- Ownership category
- akta.pro rank
Knowledge Ecology International industry classification
Industry- Product category
- Public Policy Advocacy and Research
- NAICS
- Web Search Portals, Libraries, Archives, and Other Information Services (519)
- SIC
- Services-Membership Organizations (8600)
- akta.pro primary industry
- Think Tanks, Policy Research & Public Policy Institutes (BPAGAFAO)
- akta.pro secondary industries
- Policy, Regulatory & Public Affairs Research (BPAHALAF), Government & Public Policy Publishing (Regulations, Gazettes, Legislative Tracking) (MPAJACAI)
Keywords
Where Knowledge Ecology International is headquartered
LocationHeadquarters
- HQ city
- Washington
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Knowledge Ecology International business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Others
Revenue model
- Donations and Grants: KEI operates as a non-profit organization funded through donations and grants from individuals and organizations supportive of their mission to promote access to knowledge and medicine.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Knowledge Ecology International product offering
Product offeringCore offering
KEI conducts policy research, legal analysis, and advocacy at the intersection of intellectual property, trade, and public health. It delivers formal statements at WHO, WIPO, and WTO governing body meetings, publishes briefing notes and analysis, maintains public databases of FOIA documents and drug/patent information, and submits comments to US and international policymakers on issues including pandemic preparedness, compulsory licensing, technology transfer, and government patent licensing practices.
Product overview
Knowledge Ecology International (KEI) is a non-profit research and advocacy organization focused on knowledge ecology, intellectual property rights, access to medicines, and global health policy. The organization does not operate traditional commercial products or software services. Instead, KEI publishes research, briefing notes, databases (including DrugDatabase.Info and the KEI Collection on the Internet Archive), and provides policy advocacy and comments to international organizations including WHO, WIPO, WTO, and various government bodies.
Differentiator
Problem solved
Functional benefit
Products and services
- Policy Advocacy and Research Services Research, legal analysis, and direct advocacy delivered by KEI on the intersection of intellectual property, trade policy, and public health, aimed at policymakers and international organizations.
- Briefing Notes and Policy Publications Freely available briefing notes, articles, and analytical papers (e.g., KEI Briefing Note 2026:4 on the WIPO Broadcast Treaty) covering WHO, WIPO, and WTO negotiating topics.
- DrugDatabase.Info Public reference database on drugs, patents, and related policy information maintained by KEI to support access-to-medicines analysis.
- KEI Collection on the Internet Archive Public archival collection of KEI's historical documents, FOIA releases, and policy materials hosted on the Internet Archive.
- Formal Statements and Interventions at International Bodies Official statements, interventions, and proposed negotiating text delivered by KEI at WHO, WIPO, and WTO governing body meetings (e.g., PABS Annex proposals, WHA 79 statements, CDIP opening statements).
- Government Agency Comments and Submissions Formal comments and submissions to US agencies such as NIH, FDA, USTR, and HHS on licensing proposals and policy matters (e.g., comments on the prospective OncoVanta exclusive patent license).
Quantifiable outcome
- KEI statements are regularly incorporated into WHO, WIPO, and WTO official records and negotiating texts
- +1 more outcomes
Companies that use Knowledge Ecology International
Customer profileSegments3 records
Ideal customer profiles3 records
Knowledge Ecology International technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Knowledge Ecology International partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core, major and minor.
- Medicines Patent Pool (MPP)coreThe National Institutes of Health (NIH) granted a royalty-free nonexclusive license to the Medicines Patent Pool for patents on darunavir, an HIV protease inhibitor. KEI advocated for this license as a model for voluntary licensing of government-funded patents to improve access to affordable medicines in low- and middle-income countries.
- World Health Organization (WHO)coreKEI is an accredited non-state actor at WHO, enabling participation in World Health Assemblies, Executive Board meetings, and negotiating bodies for pandemic agreements. They regularly deliver statements and participate in official sessions.
- Health Action InternationalcoreKEI collaborates with Health Action International on joint constituency statements at WHO, including coordinated advocacy on the WHO Pandemic Accord negotiations.
- OxfamcoreKEI partners with Oxfam on joint constituency statements and coordinated advocacy at WHO governing body meetings on pandemic preparedness and access to medicines.
- World Blind UnioncoreKEI collaborates with World Blind Union on joint constituency statements at WHO meetings, particularly on issues affecting access to health technologies.
- World Council of ChurchescoreKEI partners with World Council of Churches on joint constituency statements at WHO governing body meetings.
- Universities Allied for Essential Medicines (UAEM)majorKEI joined with UAEM and individual academics (Dr. Christopher Morten, Dr. Reshma Ramachandran) in submitting amicus briefs on FOIA and transparency matters, particularly regarding COVID-19 government contracts.
- Medicines Law & Policy (ML&P)majorKEI co-convenes side events with Medicines Law & Policy at WHO headquarters on topics including technology transfer and pandemic preparedness.
- InnovarteminorKEI co-organizes side events with Innovarte at WIPO on patent limitations and exceptions, including a 2024 event on best and worst practices for patent exceptions.
Scale indicators1 record
Recent moves2 records
Expansion highlights5 records
Knowledge Ecology International competitors and assessment
Company assessmentDirect peers
- Treatment Action Group: US-based activist and research organization focused on HIV, TB, and HCV treatment access. Comparable advocacy operating model and WHO-engagement footprint to KEI.
- Public Citizen: DC-based consumer and public-health advocacy organization that lobbies on access to medicines, drug pricing, and trade policy. Highly comparable to KEI in mission, geography, and use of regulatory comment processes at US agencies and Congress.
- Health Action International: Amsterdam-based NGO that advocates for access to essential medicines and rational drug use. Direct peer: KEI lists HAI as a core coalition partner for joint WHO constituency statements.
- Medicines Law & Policy: Specialized advocacy and analysis organization on pharmaceutical IP law. Direct peer: KEI co-convenes WHO side events with ML&P on technology transfer and pandemic preparedness.
- Third World Network: International network of organizations working on trade, IP, and development issues, including access to medicines and WTO negotiations. Comparable focus on global-south perspectives in IP-health policy.
- Médecins Sans Frontières Access Campaign: MSF's access-to-medicines advocacy arm engages directly with WHO, WIPO, and WTO on IP flexibilities, transparency, and pandemic preparedness. Closely comparable focus area and multilateral engagement profile to KEI.
- Universities Allied for Essential Medicines: Student-and-academic network advocating for access to medicines and equitable licensing of university-funded research. Direct peer: KEI has jointly filed amicus briefs with UAEM on COVID-19 government contract transparency.
Broad incumbents
- Oxfam International: Large international NGO with a global access-to-medicines campaign that engages WHO and WTO. KEI is a formal coalition partner of Oxfam for joint constituency statements; broader scope but overlapping advocacy portfolio.
- Open Society Foundations: Large philanthropic foundation that funds access-to-medicines and public health advocacy work across multiple NGOs, including organizations in KEI's coalition network. Operates as an enabling funder/incumbent in the same policy space.
Emerging players
- Drugs for Neglected Diseases initiative: Non-profit R&D organization developing treatments for neglected diseases; while primarily a product developer rather than advocate, it operates in the same access-to-medicines ecosystem and engages WHO on IP and access frameworks.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Knowledge Ecology International social profiles
Digital presenceKnowledge Ecology International financial estimates
Financial estimateRevenue estimate
Valuation estimate
Knowledge Ecology International leadership team
Management profileNumber of profiles
Profiles3 records
Knowledge Ecology International funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Knowledge Ecology International M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Knowledge Ecology International
What does Knowledge Ecology International do?
KEI conducts policy research, legal analysis, and advocacy at the intersection of intellectual property, trade, and public health. It delivers formal statements at WHO, WIPO, and WTO governing body meetings, publishes briefing notes and analysis, maintains public databases of FOIA documents and drug/patent information, and submits comments to US and international policymakers on issues including pandemic preparedness, compulsory licensing, technology transfer, and government patent licensing practices.
Is Knowledge Ecology International a public or private company?
Knowledge Ecology International is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was Knowledge Ecology International founded?
Knowledge Ecology International was founded in 2006. It employs 1 to 10 people.
Where is Knowledge Ecology International based?
Knowledge Ecology International is headquartered in Washington, United States, in the North America region.
How does Knowledge Ecology International make money?
One revenue line is on record: donations and Grants.
Who are Knowledge Ecology International's main competitors?
Direct peers on record are Treatment Action Group, Public Citizen, Health Action International, Medicines Law & Policy, Third World Network, Médecins Sans Frontières Access Campaign and Universities Allied for Essential Medicines. Broad incumbents are Oxfam International and Open Society Foundations. Drugs for Neglected Diseases initiative is listed as an emerging player.
Does Knowledge Ecology International have an API?
No public API is recorded for Knowledge Ecology International.
What industry is Knowledge Ecology International in?
Knowledge Ecology International's product category is Public Policy Advocacy and Research. Its primary akta.pro industry code is BPAGAFAO, Think Tanks, Policy Research & Public Policy Institutes, with a secondary code of BPAHALAF, Policy, Regulatory & Public Affairs Research. Its NAICS code is 519 and its SIC code is 8600.